title: Cancer immunotherapy in patients with preexisting autoimmune disorders.
abstract: Patients with preexisting active autoimmune disorders were excluded from clinical trials of immune checkpoint inhibitors. However, patients with autoimmune disorders are diagnosed with cancer at least as frequently as the global population, and clinicians treating patients outside clinical trials have generally been reluctant to offer cancer immunotherapy to this patient group. In this brief article, we review the most recent literature on the efficacy and safety of CTLA-4- and PD-1-blocking antibodies in patients with preexisting autoimmune disorders.
authors.affiliation: Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. Marco.Donia@regionh.dk.|Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark. Marco.Donia@regionh.dk.
authors.forename: Marco
authors.initials: M
authors.lastname: Donia
authors.affiliation: Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.|Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Magnus
authors.initials: M
authors.lastname: Pedersen
authors.affiliation: Center for Cancer Immune Therapy, Department of Hematology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.|Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Inge Marie
authors.initials: IM
authors.lastname: Svane
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications* / Q000276:immunology; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D009369:Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000209:etiology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D012306:Risk; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen; D061026:Programmed Cell Death 1 Receptor
keywords: Autoimmune diseases; Autoimmune disorders; CTLA-4; Cancer immunotherapy; Checkpoint inhibitors; Immunotherapy; Ipilimumab; Melanoma; Nivolumab; PD-1; Pembrolizumab